Preparing a Greek HTA Submission: The Five Criteria the Committee Weighs

The Greek HTA Committee does not simply ask whether a medicine works. It weighs five distinct questions, and a dossier built around those questions is easier to assess than one adapted from a generic global template.

Who assesses what

Medicines are assessed by the HTA Committee, which operates under the National Organisation for Medicines (EOF) and issues recommendations. A separate Negotiation Committee sitting within EOPYY handles economic evaluation and price negotiation, and the Minister of Health makes the final decision. The marketing authorisation holder submits a standardised dossier and an assessment fee.

The five criteria

Published descriptions of the framework identify five considerations.

  • Clinical benefit of the product.
  • Comparison with existing reimbursed treatments, which requires a defensible choice of comparator.
  • Reliability of the clinical study data, including design, endpoints and any limitations.
  • Cost-effectiveness.
  • Budget impact for the payer.

Making the dossier fit the criteria

A common mistake is to submit a global value dossier unchanged. Local reviewers need the comparator to reflect Greek practice, the population to reflect patients who will actually be treated, and the economic case to speak to Greek budgets. Where the evidence is uncertain, say so and explain how the uncertainty has been addressed, rather than leaving the committee to discover it.

Outcomes and what follows

The published review of the first years reported that most recommendations were fully positive, with smaller shares restricted or negative. A restricted recommendation shapes the eligible population and therefore the budget impact, so the question of which patients you are asking to be reimbursed deserves attention early. A rejected applicant may resubmit after three months.

A practical dossier checklist

Before submission, check each of the following. Is the comparator one that Greek clinicians use and that is already reimbursed? Is the target population defined in terms that match the proposed reimbursement conditions? Are the strengths and limitations of the pivotal studies described honestly? Is the economic model consistent with the clinical evidence and with the proposed price? And does the budget impact reflect realistic uptake in the Greek setting?

It is also sensible to prepare for questions rather than only for the written submission. The committees may ask for clarification, and consistent, fast answers reflect well on the application. Agree internally who will respond, which data are available, and what flexibility exists on price or conditions before the discussion begins.

How PQRA helps

PQRA can help adapt a global evidence package into a standardised Greek submission, check the dossier against the five assessment criteria, and prepare the company for the interaction with the HTA and Negotiation Committees.

If you are preparing a Greek reimbursement application, Contact PQRA.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *